Ngozi Osondu, MD
Infectious Disease · Phoenix, AZNPI 1598778177
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.6% of the total across 244 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Gilead at 28.1% of the total. Among infectious disease clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 244 payments — averaging $22.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Viiv Healthcare Company$1K
- Insmed, Inc.$678
- Merck$554
- Astellas Pharma US Inc$218
- Paratek Pharmaceuticals, Inc.$215
- plus $1K from 14 others
What the payments were for
- Food & beverage$5,00892%
- Education$4568%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 61 | $1,534 |
| Viiv Healthcare Company | 62 | $1,062 |
| Insmed, Inc. | 31 | $678 |
| Merck | 23 | $554 |
| Astellas Pharma US Inc | 4 | $218 |
| Paratek Pharmaceuticals, Inc. | 6 | $215 |
| Johnson & Johnson | 12 | $184 |
| Janssen Products, LP | 2 | $184 |
| Melinta Therapeutics, LLC | 7 | $143 |
| Shionogi Inc | 8 | $136 |
| La Jolla Pharmaceutical Company | 3 | $126 |
| AbbVie(2 entities) | 8 | $125 |
| Theratechnologies Inc. | 6 | $111 |
| Napo Pharmaceuticals Inc | 3 | $61 |
| Vyera Pharmaceuticals, LLC | 2 | $32 |
| Aimmune Therapeutics, Inc. | 2 | $31 |
| EMD Serono, Inc. | 1 | $22 |
| Mayne Pharma Commercial LLC | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Nabriva Therapeutics, PLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,464 in reported general payments places this provider in the 90th percentile of 146 infectious disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 161 | $633,046 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 13 | $54,826 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 12 | $50,705 |
| DovatoDolutegravir Sodium/Lamivudine | 15 | $47,178 |
| PrezcobixDarunavir/Cobicistat | 17 | $37,896 |
| TivicayDolutegravir Sodium | 15 | $36,741 |
| DescovyEmtricitabine/Tenofov Alafenam | 14 | $34,415 |
| ErtapenemErtapenem Sodium | 78 | $33,894 |
| IsentressRaltegravir Potassium | 13 | $26,098 |
| OzempicSemaglutide | 17 | $17,026 |
| JardianceEmpagliflozin | 16 | $10,198 |
| Rifabutin | 11 | $6,489 |
| Cefepime Hcl | 19 | $5,216 |
| Daptomycin | 22 | $4,165 |
| Vancomycin Hcl | 23 | $3,087 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $1,534 | $667,461175 claims |
| Viiv Healthcare CompanyTriumeq, Dovato, Tivicay | $1,062 | $134,62442 claims |
| Johnson & JohnsonPrezcobix | $184 | $37,89617 claims |
| MerckIsentress | $554 | $26,09813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 146 infectious disease providers in Arizona.
Other infectious disease in Phoenix
- Thanes VanigPhoenix$258K
- Vipul GanatraPhoenix$151K
- Ana MoranPhoenix$35K
- Robert OrensteinPhoenix$26K
- Adriana GaidiciPhoenix$20K
- Dwight ClarkePhoenix$18K
- Ndidiamaka ObiesiePhoenix$12K
- Mirella MircescuPhoenix$4K
- Rebekah SensenigPhoenix$3K
- Edwin YuPhoenix$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.